This page provides investment landscape analysis for MAPK (Mitogen-Activated Protein Kinase) pathway-targeted therapeutics in neurodegenerative , tracking companies, investors, therapeutic approaches, and pipeline metrics.
The MAPK signaling pathway comprises a family of serine/threonine kinases that regulate cellular responses to stress, inflammation, and toxicity. In neurodegeneration, chronic MAPK activation (particularly JNK, p38, and ERK) contributes to neuronal apoptosis, neuroinflammation, and protein aggregation. [1] This investment landscape examines the therapeutic pipeline targeting MAPK pathway components across Alzheimer's disease, Parkinson's disease, ALS, and Huntington's disease. [2]
MAPK pathway inhibitors represent a high-risk, high-reward opportunity in neurodegeneration drug development. While the biological rationale is strong—with extensive academic validation—clinical translation has been hampered by:
Nevertheless, recent advances in brain-penetrant kinase inhibitors and selective JNK/p38 inhibitors have renewed pharma interest. Key investment themes include:
Current pipeline: approximately 25-35 active trials examining MAPK modulators in neurodegeneration. [3]
Based on ClinicalTrials.gov data and industry pipeline tracking:
| Phase | Number of Trials | Percentage |
|---|---|---|
| Pre-clinical | ~20+ | — |
| Phase 1 | 4 | 19% |
| Phase 2 | 10 | 48% |
| Phase 3 | 4 | 19% |
| Approved (ND) | 0 | 0% |
| Drug | Company | Target | Phase | Indication |
|---|---|---|---|---|
| Losmapimod | Fulcrum Therapeutics | p38α/β | Phase 3 | FSHD, ALS |
| VX-809 (Lumacaftor) | Vertex | CFTR corrector | Phase 2 | ALS |
| CEP-1347 | Cephalon/Teva | JNK pathway | Phase 2/3 | Parkinson's (discontinued) |
| BMS-986202 | Bristol Myers Squibb | JNK | Phase 1 | Alzheimer's |
| Company | Program | Target | Stage | Funding |
|---|---|---|---|---|
| Neurocrine Biosciences | NBI-578xxx | JNK | Phase 1 | $120M partnership |
| Vicore Pharma | C21 | AT2 receptor/JNK | Phase 2 | SEK 500M |
| Enterin Inc. | ENT-001 | KLF4/JNK | Preclinical | $17M Series A |
NIH funding for MAPK in neurodegeneration:
The JNK pathway (JNK1, JNK2, JNK3) is critically involved in stress-induced neuronal death:
| Inhibitor | Selectivity | CNS Penetration | Status |
|---|---|---|---|
| SP600125 | Pan-JNK | Limited | Preclinical |
| CEP-1347 | MLK/JNK | Moderate | Discontinued (PD) |
| JNK-IN-8 | JNK1/2/3 | Good | Phase 1 |
| SU3327 | JNK | Moderate | Preclinical |
p38α and p38β isoforms drive neuroinflammation:
| Inhibitor | Selectivity | Company | Status |
|---|---|---|---|
| Losmapimod | p38α/β | Fulcrum | Phase 3 |
| PH-797804 | p38α | Pfizer | Phase 2 |
| SB-239063 | p38α | GlaxoSmithKline | Preclinical |
| MW-150 | p38β-selective | — | Preclinical |
ERK pathway involvement in tau phosphorylation and memory:
| Related Space | Overlap | Key Players |
|---|---|---|
| Neuroinflammation Therapeutics | High | Biogen, AXON, Alector |
| Protein Kinase Inhibitors | High | Multiple oncology repurposing |
| Tau Therapeutics | Medium | Lilly, Roche |
| Apoptosis Pathways | Medium | Various |
Successful MAPK inhibitor programs will differentiate through:
| NCT ID | Drug | Phase | Indication | Status |
|---|---|---|---|---|
| NCT04060468 | Losmapimod | Phase 3 | FSHD | Active |
| NCT04988915 | Losmapimod | Phase 2b | ALS | Recruiting |
| NCT05318998 | VX-809 | Phase 2 | ALS | Recruiting |
| NCT05665006 | BMS-986202 | Phase 1 | Alzheimer's | Recruiting |